2. Antibody-drug Conjugate/ADC Related
  3. Antibody-Drug Conjugates (ADCs)
  4. Sirtratumab vedotin

Sirtratumab vedotin  (Synonyms: AGS15E; ASG-15ME; 1vcMMAE)

Cat. No.: HY-P99595
Technical Support

Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker.

For research use only. We do not sell to patients.

Sirtratumab vedotin Chemical Structure

Sirtratumab vedotin Chemical Structure

CAS No. : 1824663-83-3

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Sirtratumab vedotin Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker[1].

In Vitro

Sirtratumab vedotin (ASG15-ME) shows high-affinity binding to SLITRK6 expressed on SW780 cells with a Kd of 0.018 nM[1].
Sirtratumab vedotin (10 μg/mL; 1 h) internalizes after binding to SLITRK6[1].
Sirtratumab vedotin (120 h) inhibits CHP-212 cell survival with an IC50 of 0.99 nM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sirtratumab vedotin Related Antibodies

Cell Viability Assay[1]

Cell Line: CHP-212 and IGR-OV1 cells
Concentration:
Incubation Time: 120 h
Result: Showed a dose-dependent inhibition of CHP-212 cell survival with an IC50 of 0.99 nM. Had no effect on IGR-OV1 cells (SLITRK6 negative) when applied at the same concentrations.
In Vivo

Sirtratumab vedotin (ASG15-ME; 0.25-5 mg/kg; i.v.; 2x per week for 2 or 3 weeks or single dose) shows potent antitumor activity in multiple xenograft models in mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: SCID mice, RT4 xenograft model[1]
Dosage: 5 mg/kg
Administration: Intravenous injection, single dose
Result: Caused significant inhibition.
Animal Model: SCID mice, AG-B7 and AG-B8 xenograft model[1]
Dosage: 0.25 and 0.5 mg/kg
Administration: Intravenous injection, 2x per week for 2 or 3 weeks
Result: Significantly reduced tumor volume.
Animal Model: SCID mice, the lung xenograft model NCI-H322M[1]
Dosage: 3 mg/kg
Administration: Intravenous injection, 2x per week for 3 weeks
Result: Was able to cause 99% tumor growth inhibition.
CAS No.
SMILES

[Sirtratumab vedotin]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Sirtratumab vedotin Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Sirtratumab vedotin1824663-83-3AGS15E ASG-15ME 1vcMMAEAntibody-Drug Conjugates (ADCs)Antibody-Drug ConjugatesSCID miceCHP-212RT4AG-B7AG-B8NCI-H322MInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Sirtratumab vedotin
Cat. No.:
HY-P99595
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (0 KB) Français - FR (0 KB) Deutsch - DE (0 KB) Norwegian - NO (0 KB) Español - ES (0 KB) Swedish - SV (0 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.